86
Participants
Start Date
June 13, 2022
Primary Completion Date
October 5, 2022
Study Completion Date
October 5, 2022
HR18034
HR18034 low dose
HR18034
HR18034 midium dose
HR18034
HR18034 high dose
ropivacaine HCl.
ropivacaine HCl.
Beijing Tongren Hospital Affiliated to Capital Medical University, Beijing
General Hospital of Northern Theater Command, Shenyang
Affiliated Zhongshan Hospital of Dalian University, Dalian
Taizhou People's Hospital, Taizhou
The Second Affiliated Hospital of Anhui Medical University, Hefei
Central Hospital Affiliated to Shandong First Medical University, Jinan
Jiaxing Second Hospital, Jiaxing
Li Huili Hospital of Ningbo Medical Center, Ningbo
The Third Xiangya Hospital of Central South University, Changsha
the first People's Hospital of Changde, Changde
Shiyan Taihe Hospital, Shiyan
Dongguan people's Hospital, Dongguan
Nanning Second People's Hospital, Nanning
The Affiliated Hospital of Guizhou Medical University, Guiyang
Sichuan Provincial People's Hospital, Chengdu
the First Affiliated Hospital of Xi'An Jiaotong University, Xi’an
The First Affiliated Hospital of Xi'an Medical University, Xi’an
Traditional Chinese Medicine Hospital of Hebei Province, Shijiazhuang
Shanghai Hengrui Pharmaceutical Co., Ltd.
INDUSTRY